<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" 
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://openbell.ai/</loc>
    <lastmod>2026-10-26T13:27:55.709Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>1.0</priority>
  </url>
  <url>
    <loc>https://openbell.ai/support</loc>
    <lastmod>2026-10-26T13:27:55.709Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.7</priority>
  </url>
  <url>
    <loc>https://openbell.ai/privacy</loc>
    <lastmod>2026-10-26T13:27:55.709Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/terms</loc>
    <lastmod>2026-10-26T13:27:55.709Z</lastmod>
    <changefreq>monthly</changefreq>
    <priority>0.5</priority>
  </url>
  <url>
    <loc>https://openbell.ai/feed.json</loc>
    <lastmod>2026-10-26T13:27:55.709Z</lastmod>
    <changefreq>hourly</changefreq>
    <priority>0.8</priority>
  </url>
  <url>
    <loc>https://openbell.ai/news/BEAT:1793019851000</loc>
    <lastmod>2026-10-26T13:04:11.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BEAT/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>HeartBeam Receives FDA Clearance for Acute Myocardial Infarction Assessment Technology</image:title>
      <image:caption>HeartBeam (BEAT) announced that the FDA cleared its technology for assessing acute myocardial infarction. The portable ECG solution is designed to help diagnose acute cardiac events outside traditional hospital settings and supports the company’s strategy to expand remote cardiac monitoring. The article did not report financial figures or a stock-price reaction.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/MGNX:1793019779000</loc>
    <lastmod>2026-10-26T13:02:59.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/MGNX/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab</image:title>
      <image:caption>MacroGenics reported positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer, with a confirmed objective response rate of 25% and a disease control rate of 44% among 16 evaluable patients. The company described the safety profile as manageable and is enrolling 20 additional patients at 3 mg/kg every three weeks. Updated results are expected in the first half of 2027.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/AMAN:1793019779000</loc>
    <lastmod>2026-10-26T13:02:59.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/AMAN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Amanat Acquisition Corp to Merge with Corxel Pharmaceuticals</image:title>
      <image:caption>Amanat Acquisition Corp. and Corxel Pharmaceuticals have signed a definitive business combination agreement under which Corxel US will become a wholly owned subsidiary of the combined public company. The transaction is expected to generate approximately $377 million in gross proceeds, assuming no redemptions, to support global Phase 3 development of Corxel’s obesity candidate CX11. Both boards have approved the deal, which is expected to close in the first half of 2027 pending shareholder and regulatory approvals; the combined company will adopt a new name and ticker to be announced before closing.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/HLF:1793019777000</loc>
    <lastmod>2026-10-26T13:02:57.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/HLF/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>High Liner Foods Enters into Agreement to Be Acquired by Umios for C$27.00 per Share in Cash</image:title>
      <image:caption>High Liner Foods agreed to be acquired by Umios Corporation for C$27.00 per share in cash, a fully financed offer representing a 79% premium to its October 23, 2026 closing price and an 86% premium to its 20-day volume-weighted average price. The deal was unanimously approved by High Liner’s board and is supported by Thornridge, which owns about 41.4% of the company’s shares. Completion is expected in the first quarter of 2027; High Liner will become the core of Umios’ North American business, with its headquarters remaining in Nova Scotia.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/LGN:1793019769000</loc>
    <lastmod>2026-10-26T13:02:49.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/LGN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Ovintiv Inc. Agrees to Acquire Logan Energy Corp. for Approximately $890 Million</image:title>
      <image:caption>Ovintiv agreed to acquire Logan Energy for C$1.40 per share in cash, valuing the transaction at approximately $890 million (C$1.26 billion), including Logan’s net debt. The deal would add about 266,000 net acres and 420 net 10,000-foot equivalent well locations to Ovintiv’s Montney position. Closing is expected in early Q1 2027, subject to customary conditions and regulatory approvals.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/BSRR:1793019748000</loc>
    <lastmod>2026-10-26T13:02:28.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/BSRR/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Sierra Bancorp Reports Record Quarterly Income for Third Quarter 2026</image:title>
      <image:caption>Sierra Bancorp reported record quarterly income for the third quarter of 2026, with earnings per share of $1.18. The report did not provide revenue, net income, growth rates, or stock-price impacts.</image:caption>
    </image:image>
  </url>
  <url>
    <loc>https://openbell.ai/news/VITL.UN:1793019745000</loc>
    <lastmod>2026-10-26T13:02:25.000Z</lastmod>
    <changefreq>daily</changefreq>
    <priority>0.9</priority>
    <image:image>
      <image:loc>https://cdn.brandfetch.io/VITL.UN/w/400/h/400?c=1idopYfmtR7ZKg8QMud</image:loc>
      <image:title>Vital Infrastructure Property Trust Trading Halted by CIRO</image:title>
      <image:caption>CIRO halted trading in all listed securities of Vital Infrastructure Property Trust (VITL.UN) on October 26, 2026. The initial announcement did not provide a reason for the halt.</image:caption>
    </image:image>
  </url>
</urlset>